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The transcription factor T-bet (T-box expressed 
in T cells; Tbx21) is a crucial regulator of T cell 
immunity. It mediates the differentiation of 
CD4 T cells into Th1 cells and of CD8 T cells 
into Tc1 cells (Szabo et al., 2000; Mullen et al., 
2001; Sullivan et al., 2003). In effector CD8 
T cells, T-bet is an activator of interferon- 
production and correlates with increased cyto-
toxic activity (Szabo et al., 2000; Cruz-Guilloty 
et al., 2009). A recent study has found that T-bet 
is highly expressed in HIV-specific CD8 T cells 
of HIV elite controllers who control viral load 
to very low levels without therapy (Hersperger 
et al., 2011). Correspondingly, its loss has been 
observed in dysfunctional CD8 T cells of chronic 
HIV patients and in the murine LCMV model 
of chronic viral infection (Kao et al., 2011; 
Ribeiro-dos-Santos et al., 2012). Furthermore, 
it has been shown that T-bet and the homolo-
gous transcription factor Eomesodermin (Eomes) 
define two distinct states of virus-specific CD8 
T cells and their balance plays an important 
role in the control of chronic viral infection 
(Paley et al., 2012). Interestingly, retroviral 
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The transcription factor T-bet regulates the production of interferon- and cytotoxic 
molecules in effector CD8 T cells, and its expression correlates with improved control of 
chronic viral infections. However, the role of T-bet in infections with differential outcome 
remains poorly defined. Here, we report that high expression of T-bet in virus-specific CD8 
T cells during acute hepatitis B virus (HBV) and hepatitis C virus (HCV) infection was asso-
ciated with spontaneous resolution, whereas T-bet deficiency was more characteristic of 
chronic evolving infection. T-bet strongly correlated with interferon- production and 
proliferation of virus-specific CD8 T cells, and its induction by antigen and IL-2 stimulation 
partially restored functionality in previously dysfunctional T-bet–deficient CD8 T cells. 
However, restoration of a strong interferon- response required additional stimulation with 
IL-12, which selectively induced the phosphorylation of STAT4 in T-bet+ CD8 T cells. The 
observation that T-bet expression rendered CD8 T cells responsive to IL-12 suggests a 
stepwise mechanism of T cell activation in which T-bet facilitates the recruitment of 
additional transcription factors in the presence of key cytokines. These findings support a 
critical role of T-bet for viral clearance and suggest T-bet deficiency as an important 
mechanism behind chronic infection.
© 2014 Kurktschiev et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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RESULTS
T-bet is highly expressed during  
acute resolving HBV infection
Acute HBV infection resolved spontaneously in all enrolled 
patients. Therefore, we would expect up-regulation of T-bet 
in HBV-specific CD8 T cells of these individuals, in case it 
plays an important role in viral clearance. Ex vivo expression 
of T-bet was determined by intracellular flow cytometry 
combined with MHC-I pentamers detecting HBV core 18–27 
(c18-27)–specific CD8 T cells, which react with a major 
immunodominant epitope in MHC-I A0201 background. 
The frequencies of virus-specific CD8 T cells are shown 
in Table S1.
When we compared T-bet expression in patients with 
acute resolving HBV (arHBV), chronic HBV (cHBV) and 
resolved HBV (rHBV) infection, we found a significantly 
higher mean percentage of T-bet+ c18-27–specific CD8 
T cells during arHBV (57.9%) compared with cHBV (10%) 
and rHBV (0.7%; Fig. 1, A and C). Our subanalysis of anti-
HBe+ and anti-HBe cHBV patients showed no significant 
difference in T-bet expression (unpublished data). In healthy 
controls T-bet+ CD8 T cells comprised 10.3% (mean) of 
total CD8 T cells (unpublished data). Elevated T-bet expres-
sion during arHBV was confirmed for 2 additional HBV-
specific epitopes (HBV envelope 183–191 and HBV polymerase 
573–581; Fig. 1, D and E). To rule out nonspecific bystander 
up-regulation of T-bet in CD8 T cells, we determined its 
expression in non-HBV-specific CD8 T cells during acute 
HBV infection. We chose EBV-specific CD8 T cells because 
they are broadly detectable. There was no significant increase 
in T-bet+ EBV-specific CD8 T cells (mean 10.2%; unpub-
lished data). As a proof of principle, we determined antigen-
specific T-bet up-regulation in EBV-specific CD8 T cells 
(EBV BMLF-1 259–267) during acute (aEBV) and latent 
persisting (pEBV) EBV infection. 62.7% (mean) of EBV- 
specific CD8 T cells were T-bet+ in aEBV, whereas only 
10.2% were T-bet+ in pEBV. Additionally, we found a mean 
of 7.5% T-bet+ CD8 T cells specific for Influenza A (Flu; In-
fluenza A MP 58–66) in healthy controls with previously re-
solved infection, which served as control for a memory CD8 
T cell response (Fig. 1, A and C).
Strong T-bet expression in acute HCV infection  
correlates with spontaneous resolution
Whereas acute HBV infection in adults is almost universally 
cleared, acute HCV infection becomes chronic in the major-
ity of cases (Wright and Lau, 1993; Lauer and Walker, 2001). 
In our study, 50% of the patients with acute HCV developed 
chronic infection. HCV-specific CD8 T cells were detected 
by HCV-specific pentamers covering several epitopes with 
different MHC-I backgrounds. T-bet expression was deter-
mined during the earliest available time points of acute HCV 
infection that was either cleared (arHCV) or became chronic 
(acHCV) later on. All analyzed patients were viremic at this 
time. Consistent with our results found in arHBV infec-
tion, frequencies of T-bet+ HCV-specific CD8 T cells were 
overexpression of T-bet prevented CD8 T cell exhaustion in 
chronic LCMV infection, demonstrating the therapeutic po-
tential of T-bet modulation (Kao et al., 2011). However, the 
role of T-bet in human viral infections with dichotomous out-
come remains to be determined. Because HIV and LCMV 
clone13 establish chronic infection in all infected subjects, 
other pathogens would be more suitable to dissect the differ-
ences between successful versus failing immune response dur-
ing acute infection.
Human hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infection can both either resolve spontaneously or 
establish chronic infection. Virus-specific CD8 T cells play a 
causal role in the clearance of both infections, as demonstrated 
by in vivo CD8 T cell depletion in the chimpanzee model 
where all subjects challenged with HBV or HCV developed 
chronic infection (Shoukry et al., 2003; Thimme et al., 2003). 
In chronic HBV and HCV infection, virus-specific CD8 
T cells gradually lose their effector functions and become in-
creasingly dysfunctional (Lechner et al., 2000a; Gruener et al., 
2001; Boni et al., 2007). One hallmark of severe dysfunction 
is the lack of antigen-specific interferon- production by 
T cells (Lechner et al., 2000b). Although the molecular mech-
anisms behind T cell dysfunction are the focus of intensive 
research (Bowen et al., 2004; von Hahn et al., 2007; Wherry, 
2011) it is yet unknown how far impaired regulation of 
T-bet might be involved in the development of chronic HBV 
and HCV infection.
In this study, we determined the expression of T-bet 
in virus-specific CD8 T cells during acute HBV and HCV 
infection and examined its correlation with the clinical 
outcome. T-bet was highly expressed in spontaneously re-
solving but deficient in chronic-evolving infection. When 
we further characterized the functional correlates behind 
these differential expression patterns, we found a strong as-
sociation of T-bet with antigen-specific proliferation and 
interferon- production by virus-specific CD8 T cells. In-
duction of T-bet by antigen or IL-2 recovered antigen-
specific proliferation but was not sufficient to restore 
interferon- expression. However, restoration of a strong 
interferon- response in previously dysfunctional CD8 
T cells was achieved by additional stimulation with IL-12, 
which selectively induced phosphorylation of STAT4 
(pSTAT4) in T-bet+ CD8 T cells. This is consistent with 
previous findings that T-bet and STAT4 cooperate in the 
transcriptional control of interferon- (Thieu et al., 2008). 
The observation that T-bet rendered CD8 T cells suscep-
tible to IL-12 suggests a stepwise mechanism of T cell acti-
vation in which T-bet facilitates the recruitment of additional 
transcription factors in the presence of key cytokines, and 
thus contributes to the adjustment of an appropriate 
T cell response.
These findings indicate a critical role of T-bet for a suc-
cessful CD8 T cell response against HBV and HCV infection 
and suggest that impaired induction of T-bet could be an im-
portant mechanism involved in CD8 T cell dysfunction dur-
ing chronic viral infections.
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T cells we performed longitudinal measurements of T-bet 
expression in 5 patients with arHBV, 4 patients with acHCV, 
and 4 patients with arHCV. This kinetics profile contained 
data from 3 different time points within 6 mo after symptom 
onset. The first time point (t1) was defined as the earliest 
available patient sample obtained within 1 mo after onset of 
acute symptoms. The following analyzed time points were 
1–3 mo (t2) and 3–6 mo (t3) after symptom onset, respec-
tively. In arHBV, we observed a high percentage of T-bet+ 
c18-27–specific CD8 T cells at t1 (mean, 73.1%), which 
gradually decreased to 40.3% at t2 and 21.8% at t3 (Fig. 2, 
left). In arHCV infection, we found a similar pattern as seen 
significantly higher in patients with spontaneous resolution 
of HCV infection (arHCV; mean, 66.3%) compared with 
patients with chronic-evolving infection (acHCV; mean, 14%; 
Fig. 1, B and C). The frequencies of T-bet+ HCV-specific 
CD8 T cells in long-term chronic (cHCV; mean, 4.5%) and 
long-term resolved (rHCV; mean, 6.9%) HCV infection were 
comparable to those found in cHBV and rHBV.
T-bet deficiency in early acute HCV  
precedes chronic-evolving infection
To characterize the duration of T-bet up-regulation and 
fluctuations in its expression levels in virus-specific CD8 
Figure 1. HBV- and HCV-specific CD8  
T cells express high amounts of T-bet dur-
ing acute spontaneously resolving infec-
tion. PBMCs were isolated from (A) patients 
with arHBV, cHBV, rHBV (top), aEBV, pEBV, or 
resolved Flu infection (bottom) and (B) pa-
tients with arHCV (top left), rHCV (top right), 
acHCV (bottom left), or cHCV infection (bot-
tom right) and analyzed by flow cytometry. 
The outlined areas indicate the population of 
pentamer+ CD8 T cells and the numbers indi-
cate the percentage of T-bet+ (above) and  
T-bet (below) cells among total pentamer+ 
CD8 T cells. (C) Quantification of ex vivo T-bet 
expression in virus-specific CD8 T cells of the 
subjects described in A and B. Bars represent 
the mean percentage of T-bet+ pentamer+ 
CD8 T cells among total pentamer+ CD8 T cells 
of patients with arHBV (n = 19), cHBV (n = 24), 
rHBV (n = 5), arHCV (n = 7), acHCV (n = 7), 
cHCV (n = 7), rHCV (n = 7), aEBV (n = 3), pEBV 
(n = 6), and Flu (n = 6). Error bars indicate the 
SEM. *, P < 0.05; ***, P < 0.001 (Mann-Whitney-
U test). (D) Representative ex-vivo flow  
cytometry plots showing expression of T-bet 
in HBV envelope (183–191)–specific (left) and 
HBV polymerase (573–581)–specific CD8  
T cells (right) of patients with arHBV. The 
numbers indicate the percentage of T-bet+/ 
and pentamer+/ CD8 T cells among total CD8  
T cells. (E) Scatter dot plot showing the percent-
age of T-bet+ envelope (183–191)–specific 
(filled circles; n = 5) or polymerase (573–581)-
specific (open circles; n = 5) CD8 T cells among 
total pentamer+ CD8 T cells of patients with 
arHBV. The data are representative of one 
experiment due to limited patient material.
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acHCV (10.5%), and cHCV (8.7%). In contrast, T-bet+/
Eomes cells, which comprised the majority of virus-specific 
CD8 T cells, were significantly more frequent during 
arHBV (mean, 38.5%) and arHCV (54.6%) as compared 
with cHBV (9.2%), acHCV (11.7%), and cHCV (13.4%). 
Interestingly, we consistently observed a population of Eomes+/
T-bet+ cells, which were significantly increased in arHBV 
(19.4%, mean) and arHCV (11.7%) compared with cHBV 
(0.8%), acHCV (2.3%), and cHCV (1.1%).
T-bet and PD-1 are coexpressed during acute  
but not in chronic HBV or HCV infection
PD-1 is the hallmark inhibitory receptor found on exhausted 
CD8 T cells. As recent publications have shown that T-bet can 
suppress PD-1 we examined the coexpression of both factors in 
HBV and HCV infection ex vivo. T-bet and PD-1 are highly 
coexpressed in virus-specific CD8 T cells during resolving 
arHBV (mean 51.2%) and arHCV (45%), whereas the frequen-
cies of T-bet+/PD-1+ virus-specific CD8 T cells were signifi-
cantly lower in cHBV (11%), acHCV (7.6%), and cHCV 
(0.7%; Fig. 3, B and E). In contrast, the mean percentage of 
PD-1+/T-bet virus-specific CD8 T cells was highest in cHBV 
(65.7%) and cHCV (50.9%) as compared with acute arHBV 
(37.7%), arHCV (19.2%), and acHCV (19%) infection.
Mutually exclusive expression of T-bet and CD127
In the murine LCMV infection model, it has been shown 
that T-bet promotes the differentiation of effector and effector–
memory CD8 T cells at the cost of central–memory cells by 
repression of IL-7R (CD127; Intlekofer et al., 2007). We 
investigated if T-bet can repress CD127 expression on virus-
specific CD8 T cells during HBV and HCV infection, as this 
could affect the generation of memory CD8 T cells. T-bet+/
CD127+ virus-specific CD8 T cells were rare (means: arHBV, 
3.7%; cHBV, 7.7%; arHCV, 4.9%; acHCV, 3.1%; and cHCV, 
5.9%). The T-bet+/CD127 population showed higher fre-
quencies in resolving (means: arHBV, 61.8%; arHCV, 48.9%) 
as compared with chronic-evolving infections (cHBV, 5.8%; 
in HBV-specific CD8 T cells during arHBV (mean t1 = 67.1%; 
t2 = 54.5%; and t3 = 29.2%) with high initial expression of 
T-bet in HCV-specific CD8 T cells, which slowly decreased 
over the 6 mo of follow up (Fig. 2, middle). In contrast, in 
acHCV T-bet expression was low right from the beginning 
(mean: t1 = 14.8%; t2 = 12.6%, and t3 = 11.9%; Fig. 2, right). 
The 4 patients with acHCV were further differentiated into 
partial (n = 3) versus no controllers of viremia (n = 1) accord-
ing to the evolution of viral load between t1 and t3 (Table 1). 
No correlation was found between T-bet or Eomes expres-
sion and quality of viral control. However, studies on larger 
cohorts would be required to confirm this observation.
Eomes and T-bet can be coexpressed and define  
different subsets of virus-specific CD8 T cells
As recent literature has reported that Eomes, which bears 
strong homology with T-bet, can compensate for T-bet de-
ficiency in CD8 T cells of T-bet/ mice, we investigated 
if Eomes is associated with a successful immune response in 
human HBV and HCV infection as well (Intlekofer et al., 
2005). Furthermore, one study has demonstrated that the 
balance of two subsets of CD8 T cells, T-bet (high) and 
Eomes (high), respectively, is important for the control of 
murine LCMV and chronic HCV infection (Paley et al., 
2012). Therefore, we examined the co-expression of T-bet 
and Eomes in virus-specific CD8 T cells under several con-
ditions (Fig. 3, A and D). We found that Eomes+/T-bet 
CD8 T cells did not show any significant difference be-
tween arHBV (10%, mean), cHBV (8.9%), arHCV (3%), 
Figure 2. T-bet expression is lost early in acute chronic-evolving HCV infection. Percentage of T-bet+ pentamer+ CD8 T cells among total pen-
tamer+ CD8 T cells of patients with arHBV (n = 5; left), arHCV (n = 4; middle), and acHCV (n = 4; right) was determined by ex vivo flow cytometry at the 
indicated time points. Data show the mean percentages and are representative of one experiment due to limited patient material. Error bars indicate SEM.
Table 1. Kinetics of viral load in acute chronic-evolving HCV 
infection
Patient t1 viral load [IU/ml] t3 viral load [IU/ml]
P1 1,300 14
P2 2,980 15
P3 110,000 150
P4 66,000 9,350,000
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Figure 3. Expression of T-bet is associated with distinct phenotypes of virus-specific CD8 T cells. Ex vivo expression of T-bet, Eomes, PD-1, and 
CD127 in PBMCs from patients with acute HBV or HCV infection was analyzed by flow cytometry on the earliest available samples obtained within 3 wk 
of acute symptom onset. The data on cHBV and cHCV patients were obtained at any time point during chronic infection. (A) Contour plots show ex vivo 
coexpression of T-bet and Eomes in virus-specific CD8 T cells of patients with arHBV, cHBV, arHCV, acHCV, and cHCV infection. The numbers indicate the 
percentage of T-bet+/ and Eomes+/ CD8 T cells among pentamer+ CD8 T cells. (B) Representative contour plots of T-bet and PD-1 coexpression as 
described in (A). (C) Representative contour plots of T-bet and CD127 coexpression as described in A. (D) Mean percentage of pentamer+ CD8 T cells with 
a T-bet+/Eomes, T-bet/Eomes+, and T-bet+/Eomes+ phenotype as determined by flow cytometry. Data were obtained from arHBV (n = 19), cHBV (n = 24), 
arHCV (n = 7), acHCV (n = 7), and cHCV (n = 7) patients. (E) Mean percentage of pentamer+ CD8 T cells with T-bet+/ PD-1+ and T-bet/ PD-1+ phenotype 
found in the patients described in D. (F) Mean percentage of T-bet+/ CD127+, T-bet/ CD127+, and T-bet+/CD127 analogous to D. All error bars indicate 
SEM. ***, P < 0.001 (Mann-Whitney-U test). Data are representative of one experiment due to limited patient material.
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literature (Lighvani et al., 2001; Ylikoski et al., 2005) could in-
crease T-bet and interferon- expression in virus-specific CD8 
T cells of chronic HBV patients. We tested several cytokines in 
different concentrations (see Materials and methods) for their 
potential to induce T-bet in CD8 T cells (Fig. 4 B). The only 
cytokine that significantly induced T-bet was IL-2. Therefore, 
we wanted to examine if T-bet induction by IL-2 was directly 
coupled with interferon- production. We found a significant 
but weak increase of T-bet+/interferon-+ CD8 T cells after 
stimulation with IL-2+c18-27 (mean, 0.154%) compared with 
stimulation with c18-27 antigen alone (mean, 0.012%) or the 
control (mean, 0.008%). However, we observed that stimula-
tion with IL-2+IL-12+c18-27 resulted in a much stronger 
increase of T-bet+/interferon-+ CD8 T cells (mean 1.981%), 
whereas IL-12+c18-27 was not able to induce the same effect 
in the absence of IL-2 (0.014%). IL-2+IL-12 induced consider-
able background stimulation (1.191%; Fig. 4, A and C).
acHCV, 13.5%; cHCV, 10.8%). On the contrary, T-bet/
CD127+ cells were more frequent in chronic-evolving 
(means: cHBV, 69.8%; acHCV, 29.5%; cHCV, 50.4%) than 
in resolving infection (arHBV, 4.8%; arHCV, 10.4%; Fig. 3, 
C and F).
Induction of T-bet by IL-2 facilitates antigen- 
specific interferon- production in HBV-specific  
CD8 T cells in cooperation with IL-12
To examine the effects of T-bet on CD8 T cell functionality, 
we compared its coexpression with interferon- and perforin 
in CD8 T cells of healthy controls, which were nonspecifically 
activated by TCR-stimulation with CD3+CD28. The vast 
majority of interferon-– and perforin-producing stimulated 
CD8 T cells were T-bet+ (unpublished data). Next, we ad-
dressed the question of whether specific stimulation with anti-
gen (c18-27) or cytokines described as T-bet inducers in 
Figure 4. Antigen-specific interferon- production correlates with T-bet and can be restored by IL-2+IL-12 co-stimulation. PBMCs of pa-
tients with cHBV (n = 11) were cultured for 3 d in culture medium (control) containing either HBV-c18-27 antigen (Ag), c18-27 antigen+IL-2 (Ag+IL-2), 
c18-27 antigen+IL-12 (Ag+IL-12), IL-2+IL-12, c18-27 antigen+IL-2+IL-12 (Ag+IL-2+IL-12), or CD3+CD28. On day 3 antigen-treated groups were  
restimulated with antigen and all groups were incubated for 6 h in the presence of Brefeldin A before intracellular flow cytometry was performed.  
(A) Expression of T-bet and interferon- by CD8 T cells. The numbers indicate the percentage of T-bet+/ and interferon-+/ CD8 T cells among total CD8 
T cells. (B) Mean induction of T-bet by treatment with the respective cytokines. Induction was defined as the percentage of T-bet+ CD8 T cells after stimu-
lation subtracted by the percentage of T-bet+ CD8 T cells in unstimulated controls. Error bars represent the SEM. (C) Mean percentage of T-bet+ interferon-+ 
CD8 T cells after stimulation. Error bars indicate the SEM. Data are representative of one experiment due to limited patient material. ***, P < 0.001 (Mann-
Whitney-U test).
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importance of T-bet in HIV and LCMV clone 13 that univer-
sally establish chronic infection, we assessed its role in human 
HBV and HCV infection that allowed us the direct compari-
son of successful versus failing CD8 T cell response against 
the same pathogen (Hersperger et al., 2011; Kao et al., 2011; 
Ribeiro-dos-Santos et al., 2012). Our most important finding 
is that expression of T-bet in virus-specific CD8 T cells was 
strongly associated with clearance of acute HCV infection. 
HCV-specific CD8 T cells in acute chronic-evolving HCV 
infection, though broadly detectable, failed to clear HCV in-
fection and were deficient in T-bet expression. In acute HBV 
infection, increased expression levels of T-bet were observed 
in patients who later resolved the disease, whereas expression 
was lost in dysfunctional CD8 T cells in spite of viral persis-
tence during long-term chronic infection. As acute HBV in-
fection rarely takes chronic course in adults, we were not able 
to confirm T-bet deficiency in HBV-specific CD8 T cells of 
such patients. Therefore, further studies will be required to es-
tablish a definitive association between T-bet expression and 
clinical course of HBV infection. All patients who later con-
trolled viral replication had high expression of T-bet in virus-
specific CD8 T cells, and we confirmed the same pattern in 
acute and latent persisting EBV infection. These data provide 
further evidence for a central role of T-bet for a successful 
virus-specific CD8 T cell response in self-limiting human 
viral infections whereas T-bet deficiency was associated with 
chronic infection. Several studies have provided insights into 
the mechanisms behind T-bet deficiency in chronic infec-
tions. In the murine LCMV infection model, antigen persis-
tence and high viral load lead to reduced T-bet levels in CD8 
T cells, possibly by impaired T cell receptor signaling (Kao 
et al., 2011). Direct inhibition of CD8 T cell signaling by in-
teraction with viral proteins can occur as well. For example, 
HCV core protein inhibits proliferation and interferon- pro-
duction of HCV-specific T cells by blocking their C1q com-
plement receptor (Kittlesen et al., 2000). Generation of escape 
mutations can also lead to reduced T cell receptor stimulation 
(Chang et al., 1997). Interestingly, we did not observe ex vivo 
expression of T-bet and Eomes on HCV-specific CD4 T cells 
of patients with acute HCV infection, which warrants further 
investigation (Fig. S1). Of note, T-bet was readily inducible in 
CD4 T cells under Th1 culture conditions.
Our longitudinal measurements demonstrate that T-bet 
expression levels are stable over longer time spans and are not 
affected by rapid fluctuations. In acute resolving HBV and 
HCV infection, the highest expression of T-bet was observed 
at the earliest available time points and remained elevated 
compared with controls for at least 4–6 mo. In acute chronic-
evolving HCV infection, however, T-bet remained low at all 
analyzed time points. Although very early loss of previously 
induced T-bet might be one explanation, our observations of 
T-bet kinetics in resolving infection suggest that this elevation 
should be detectable for several months. As this was not the 
case, an alternative explanation could be that T-bet is only 
weakly induced and thus lost at earlier time points or is not 
induced at all.
High expression of T-bet is associated  
with strong antigen-specific proliferation
Antigen-specific proliferation of CD8 T cells is key to the gen-
eration of sufficient amounts of effector cells for control of the 
virus. We analyzed the correlation between T-bet expression and 
expansion of epitope-specific CD8 T cells upon stimulation. 
PBMCs of patients with chronic HBV were stimulated with 
either antigen c18-27 and/or cytokines IL-2 and IL-12 for 7 d 
as described in the Materials and methods. The expansion of 
c18-27–specific CD8 T cells and the correlation between T-bet 
expression and proliferation was determined by flow cytometry 
with the proliferation marker Pacific Blue succinimidyl ester 
(PBSE). The strongest expansion of c18-27–specific CD8 T cells 
was observed in the groups stimulated with antigen c18-27 
(mean, 0.7% of total CD8 T cells), IL-2+c18-27 (mean, 1.83%), 
and IL-2+IL-12+c18-27 (mean, 1.93%), which was a significant 
induction compared with controls (mean, 0.1%). Of note, IL-12 
did not significantly increase proliferation when added to 
IL-2+Ag. PBMCs stimulated with IL-2 (mean, 0.1%), IL-12 
(mean, 0.09%), or IL-2+IL-12 (mean, 0.15%) showed no increased 
frequencies of virus-specific CD8 T cells (Fig. 5, A and B). Next, 
we divided proliferating PBSE- and c18-27–specific CD8 
T cells in a T-bet+ and a T-bet subset to determine if T-bet was 
preferentially expressed in proliferating cells. We found signifi-
cantly higher frequencies of T-bet+ CD8 T cells in the groups 
with strong proliferation, whereas T-bet CD8 T cells showed 
low frequencies (Ag mean: T-bet+, 0.29%; T-bet, 0.09%; 
IL-2+Ag T-bet+, 1.12%; T-bet, 0.07%; and IL-2+IL12+Ag 
T-bet+, 1.04%; T-bet, 0.05%; Fig. 5, C and D). Interestingly, we 
observed strong induction of T-bet+ virus-specific CD8 T cells 
in the groups stimulated with antigen c18-27 (mean, 82.6% of 
specific cells) or IL-2 (mean, 56.2%) compared with IL-12 
(mean, 12.5%), and control (mean, 8.5%; unpublished data).
IL-12 selectively induces phosphorylation  
of STAT4 in T-bet+ CD8 T cells
We sought to determine the mechanism behind the much 
stronger induction of interferon- after additional stimulation 
with IL-12. STAT4 is of crucial importance for signal trans-
duction by the IL-12 receptor and is known to cooperate with 
T-bet in the regulation of the interferon- gene (Thieu et al., 
2008). Therefore, we investigated if phosphorylation of STAT4 
might be a possible explanation. PBMCs were either pretreated 
with IL-2 to induce T-bet or left unstimulated as control. On 
day 3, cells were restimulated with either IL-12 which should 
induce STAT4 phosphorylation or IL-2 as negative control. 
We found that IL-12 preferentially induced pSTAT4 in T-bet+ 
CD8 T cells (mean, 2.6%) as compared with T-bet cells 
(0.38%; Fig. 6, A and B). IL-2 restimulation minimally induced 
pSTAT4 in T-bet+ (0.3%) and T-bet CD8 T cells (0.34%) 
compared with controls (T-bet+, 0.03%; T-bet, 0.05%).
DISCUSSION
In this study, we investigated in how far T-bet is involved in 
the early events during acute infection, which are critical for 
viral clearance. Although previous studies have discovered the 
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that play an important role in the control of chronic viral infec-
tion (Pearce et al., 2003; Paley et al., 2012). As Eomes might 
compensate for the lack of T-bet in HBV and HCV infection, 
Eomes can trigger antigen-specific interferon- pro-
duction in CD8+ T cells of T-bet/ mice and, together with 
T-bet, it defines different subsets of virus-specific CD8 T cells 
Figure 5. Induction of T-bet by IL-2 and antigen is associated with antigen-specific proliferation. PBMCs of patients with cHBV (n = 10) were 
labeled with the proliferation marker PBSE and cultured for 7 d in culture medium in the presence or absence of HBV-c18-27 antigen (Ag), IL-2, or IL-12. 
Antigen c18-27 was added on day 0, and cytokines were administered on day 4 in the designated groups. Negative controls were cultured in medium 
without further supplements, while positive controls were stimulated with CD3+CD28. On day 7, cells were stained for flow cytometry. (A) Frequencies of 
pentamer+ CD8 T cells among total CD8 T cells and their PBSE labeling intensity. (B) Expression of T-bet and the frequency of pentamer+ CD8 T cells after 
stimulation. (C) Mean percentage of c18-27–specific CD8 T cells among total CD8 T cells. (D) Mean percentage of PBSE/T-bet (white) and mean per-
centage of PBSE/T-bet+ specific CD8 T cells (black) among total CD8 T cells. Error bars represent the SEM. Data are representative of one experiment due 
to limited patient material. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Mann-Whitney-U test).
 o
n
 D
ecem
ber 19, 2014
jem.rupress.org
D
ow
nloaded from
 
Published September 15, 2014
JEM Vol. 211, No. 10 
Article
2055
However, as T-bet was not expressed at later stages of infec-
tion in our analyzed samples we could not assess possible sup-
pressive effects on PD-1 ex vivo.
A successful immune response also depends on the bal-
anced differentiation of CD8 T cells into terminally differen-
tiated effector CD8 T cells and self-renewing central–memory 
CD8 T cells. Former studies demonstrated that T-bet drives 
effector CD8 T cell differentiation at the expense of central–
memory cells. Our finding that T-bet and CD127 are ex-
pressed in a mutually exclusive way fits into this hypothesis. 
It remains to be determined how far T-bet expression during 
acute infection could impair the differentiation of memory 
CD8 T cells. Of note, T-bet was down-regulated in mem-
ory CD8 T cells of patients with resolved HBV, HCV, and 
Flu infection. This could be explained by a lack of TCR 
stimulation after antigen elimination. Another possible expla-
nation is that T-bet+ CD8 T cells are short-lived effector cells 
and are lost over time (Intlekofer et al., 2005; Joshi et al., 
2007). In summary, the factor that shows the strongest corre-
lation with viral clearance is expression of T-bet. Although 
significant, the correlation of T-bet+Eomes+ or T-bet+PD-1+ 
HCV-specific CD8 T cells and viral clearance was less pro-
nounced. Interestingly, CD127 expression on virus-specific 
CD8 T cells during acute HCV infection has shown a nega-
tive correlation with viral clearance.
Because our data suggested that the association of T-bet 
with clearance of infection is not just a secondary phenomenon 
but causally involved in the mechanisms behind a successful 
immune response, we further investigated the effects of T-bet on 
proliferation and interferon- production of virus-specific CD8 
T cells. We observed that virtually all interferon-–producing 
CD8 T cells expressed T-bet as well, whereas T-bet–expressing 
CD8 T cells did not necessarily produce interferon-. We 
tested several cytokines and cytokine combinations, including 
we further analyzed its coexpression with T-bet in virus-specific 
CD8 T cells under different conditions. In contrast to the pre-
dominant T-bet+ Eomes population, which was significantly 
more frequent in acute resolving versus chronic-evolving in-
fection and correlated with viral clearance, we did not observe 
any up-regulation of Eomes+ T-bet CD8 T cells in acute 
resolving infection. Of note, this was true for patients with 
cHBV and cHCV as well, which differs from previous studies 
that have suggested up-regulation of Eomes in exhausted cells 
of patients with chronic infection (Paley et al., 2012). This 
might be explained by the fact that we focused on HBV- 
and HCV-specific peripheral blood lymphocytes, whereas the 
cited study analyzed HCV-specific intrahepatic lymphocytes 
or LCMV-specific lymphocytes in murine infection. Further-
more, a subset of T-bet+ Eomes+ cells was consistently detect-
able and showed significantly elevated frequencies in resolving 
versus chronic-evolving infection, as described for the T-bet+ 
Eomes subset. The finding that Eomes was preferentially ex-
pressed in T-bet+ CD8 T cells supports the notion of a domi-
nant role of T-bet for a functional CD8 T cell response during 
acute infection.
One recent study has shown that the expression of PD-1, 
the hallmark inhibitory receptor of exhausted CD8 T cells, 
can be repressed by T-bet in chronic murine LCMV infec-
tion. Retroviral overexpression of T-bet in CD8 T cells led 
to a sustained antiviral CD8 T cell response and down-regulation 
of several inhibitory surface receptors (Kao et al., 2011). In 
another study, induction of T-bet by third signal cytokines 
decreases PD-1 levels in chronic HBV infection and restored 
interferon- production (Schurich et al., 2013). We found 
that T-bet and PD-1 are highly coexpressed in acute infec-
tion but later on T-bet is lost while PD-1 levels remain high. 
The lack of T-bet might facilitate the high expression of 
PD-1 on dysfunctional CD8 T cells during chronic infection. 
Figure 6. IL-12 selectively induces STAT4 
phosphorylation in T-bet+ CD8 T cells. PBMCs 
of patients with cHBV (n = 7) were cultured for 3 d 
with either IL-2 or medium as control. On day 3 
cells were restimulated for 20 min with either 
IL-2 or IL-12. Controls were left unstimulated. 
Cells were then analyzed by flow cytometry. 
(A) Coexpression of T-bet and pSTAT4 in CD8  
T cells of an unstimulated control (left), PBMCs 
cultured with IL-2 and restimulated with IL-2 
(middle), and PBMCs cultured in IL-2 and restim-
ulated with IL-12 (right). Representative plots 
demonstrate the percentage of T-bet+/ and 
pSTAT4+/ CD8 T cells among total CD8 T cells.  
(B) Mean frequency of T-bet pSTAT4+ (white) 
and mean frequency of T-bet+ pSTAT4+ (black) 
CD8 T cells among total CD8 T cells after stimula-
tion with the respective cytokines. Error bars rep-
resent the SEM. Data are representative of one 
experiment due to limited patient material.  
**, P < 0.01 (Mann-Whitney-U test).
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result from impairment at different levels of this regulatory net-
work during its adjustment. Loss of HCV-specific CD4 T cell 
responses and IL-2 production as consistently observed in 
patients developing chronic infection is one mechanism that 
could interfere with proper induction of T-bet in CD8 T cells 
(Diepolder et al., 1995; Gerlach et al., 1999; Urbani et al., 
2006). Furthermore, several studies have reported that HCV 
core protein disturbs APC maturation during acute HCV infec-
tion, leading to decreased levels of IL-12, which could contrib-
ute to loss of interferon- production (Auffermann-Gretzinger 
et al., 2001; Eisen-Vandervelde et al., 2004).
Our data provide for the first time evidence for the cen-
tral role of T-bet in self-limiting human viral infections and 
for deficient T-bet induction in virus-specific CD8 T cells as 
a mechanism associated with viral persistence. T-bet induc-
tion by IL-2 and co-stimulation with IL-12 restored function 
in previously exhausted virus-specific CD8 T cells and could 
be a potential target for future therapies.
MATERIALS AND METHODS
Study subjects. Peripheral blood was obtained from patients and controls at 
the University Hospital Munich. We examined HBV-specific CD8 T cell 
responses in patients with MHC-I A0201 background and arHBV, cHBV, or 
rHBV infection. The HCV-specific CD8 T cell responses were analyzed in 
patients with arHCV, acHCV, cHCV, and rHCV HCV infection. HCV pa-
tients had MHC-I backgrounds A0101, A0201, A0301, B0701, or B3501. All 
HCV genotypes were included. Patients with acute EBV infection and 
healthy subjects served as controls. The patient characteristics are summarized 
in Table 2.
Ethics statement. This study was conducted in conformity with the ethical 
guidelines of the Declaration of Helsinki. Written informed consent was 
obtained from all patients. Approval for this study was obtained from the In-
stitutional Review Board of the medical faculty of the Ludwig-Maximilians-
University (Munich).
Diagnostic criteria. Acute hepatitis was defined as acute onset of nonspe-
cific Flu-like symptoms and jaundice in previously healthy persons with peak 
GPT elevation 10 times above the upper limit of normal. Acute HBV was 
confirmed by concomitant detection of HBsAg, HBV-DNA, or anti-HBc-
IgM and acute HCV by detection of HCV-RNA or seroconversion of anti-
HCV. Other possible causes of acute hepatitis, like autoimmune hepatitis, 
alcoholic liver disease, or toxins were excluded. Resolution of acute hepatitis 
B was confirmed by seroconversion of anti-HBs. Acute-resolving HCV was 
defined as spontaneous loss of initially detectable HCV-RNA, which re-
mained negative for at least 12 mo. In chronic-evolving acute HCV infec-
tion, HCV-RNA remained detectable for longer than 6 mo after symptom 
onset. Resolved HCV was defined as a previously cleared HCV infection 
without detection of HCV-RNA for at least 12 mo before enrollment. Di-
agnosis of chronic HCV infection was based on elevated serum GPT levels 
for at least 6 mo and the consistent detection of HCV-RNA. Chronic HBV 
was defined by detection of HBV-DNA or HBsAg for more than 6 mo. 
Acute EBV was diagnosed by acute clinical symptoms, typical hematologic 
findings, and detection of EBV-DNA.
Isolation of PBMCs. Human PBMCs were isolated from heparinized 
blood by Ficoll-Paque density-gradient centrifugation as described earlier 
and were either analyzed directly or cryopreserved (Perlmann et al., 1976).
HLA typing. DNA was extracted from PBMCs with the QIAamp DNA 
Blood Mini kit (QIAGEN) following the manufacturer’s instructions. HLA 
typing was performed as described previously (Witt et al., 2002).
interferon-, interferon-, IL-2, and IL-12, which have been 
used for induction of T-bet in recent literature and observed 
the most striking effect on T-bet induction when stimulating 
with IL-2 (Lighvani et al., 2001; Ylikoski et al., 2005). Sub-
sequent experiments revealed a similar effect by stimulation with 
antigen, which had an additive effect when combined with 
IL-2. It was surprising that antigen-stimulated proliferation in 
exhausted CD8 T cells. However, it has been previously 
shown that exhausted T cells can proliferate extensively upon 
antigen exposure without producing cytokines (Shin et al., 
2007). This fits with our experience that T cells require anti-
gen for in vitro expansion. Although IL-2 plays an important 
role for in vitro expansion, our results suggest that antigen itself 
can trigger proliferation to some extent, too. We used low 
doses of antigen because higher doses can induce anergy. In 
addition, antigen concentration was kept constant. This is dif-
ferent from the in vivo setting, where antigen levels are fluc-
tuating and can reach much higher levels as used in our 
experiments. Induction of T-bet by IL-2 and/or antigen 
strongly induced proliferation of HBV-specific CD8 T cells 
but did not induce interferon-. Restoration of a strong inter-
feron- response required additional stimulation with IL-12, 
which could be explained by the finding that T-bet can induce 
the IL-12R2 receptor, and thus make T cells more suscepti-
ble to IL-12 (Liao et al., 2011). We sought to clarify the mech-
anism behind the enhanced IFN- induction in IL-12–stimulated 
CD8 T cells and examined if STAT4, which is known as spe-
cific signal transducer of the IL-12 receptor, might be involved. 
Interestingly, we found that IL-12 selectively induced STAT4 
phosphorylation in T-bet+ CD8 T cells, which is consistent 
with previous studies that describe cooperation of T-bet and 
pSTAT4 in the induction of IFN- (Thieu et al., 2008). IL-12 
single treatment induced neither T-bet up-regulation nor 
interferon- secretion or proliferation. We observed background 
stimulation of CD8 T cells in the group stimulated with 
IL-2+IL-12 but without antigen, which can be explained in part 
by TCR-independent reactivation of CD8 T cells by cyto-
kines, as described for memory CD8 T cells (Raué et al., 
2013). One recent study has found that IL-12 induces T-bet 
and interferon- in CD8 T cells of patients with chronic 
HBV infection (Schurich et al., 2013). However, as IL-2 was 
universally added to cell culture medium in the cited study, 
considering our observations, we suggest that the observed 
effects occur only under combined treatment with both cyto-
kines. This is important, as the synergistic effects of both cy-
tokines allowed us a 200-fold reduction of the effective IL-12 
dose, thus making it more approachable for potential clinical 
trials. Although previous trials with single cytokine treat-
ment of chronic HBV and HCV infection found no signifi-
cant improvement of the clinical outcome (Pardo et al., 1997; 
Artillo et al., 1998; Zeuzem et al., 1999; Carreño et al., 2000), 
a combination treatment with reduced cytokine doses might 
be more promising.
Viral clearance requires a balanced interplay of virus-
specific CD4 T cells, CD8 T cells and APC. The various pat-
terns of viral replication seen during acute infection could 
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cells were enriched by anti-PE MACS-beads, directed against PE-labeled 
pentamers. Calculation of pentamer+ CD8 T cells was performed as pre-
viously described (Lucas et al., 2007). In brief, samples were divided in a 
preenrichment probe (10% of sample cells), which was used to determine the 
input number of CD8 T cells and a post-enrichment probe (90% of sample 
cells), which was run through miniMACS MS separation columns (Miltenyi 
Biotec). Frequencies of pentamer+ CD8 T cells were calculated by dividing 
the absolute number of pentamer+ CD8 T cells from the postenrichment 
probe by the number of CD8 T cells in the preenrichment probe × 9. Sam-
ples were acquired on a FACSCanto II flow cytometer (BD). Data were ana-
lyzed with FlowJo 9.6.1. software (Tree Star). Gating strategy excluded 
monocytes (CD14+), B-lymphocytes (CD19+), and dead cells (7-AAD+) by 
a dump channel.
Detection of phosphorylated STAT4 by intracellular phospho-flow 
cytometry. 2 × 106 PBMCs per well were incubated for 3 d with either 
IL-2 or medium as control. On day 3, cells were stimulated for 20 min with 
either IL-2 or IL-12. After fixation and permeabilization with Perm buffer 
III (BD) cells were stained with anti-pSTAT4 and anti–T-bet before analysis 
by flow cytometry.
Statistical analysis. Statistical analysis was performed with Prism 5.0 soft-
ware (GraphPad) and included 2-sided Wilcoxon matched pairs test and 
Mann-Whitney-U test for unpaired samples. Statistical significance was de-
fined as P < 0.05.
Online supplemental material. Table S1 shows the ex vivo frequencies of 
pentamer+ CD8 T cells of the patients described in Fig. 1. Fig. S1 demon-
strates flow cytometry plots and gating procedure of CD4 tetramer stainings 
of 2 patients with acute HCV (central plots). Online supplemental material 
http://www.jem.org/cgi/content/full/jem.20131333/DC1.
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Antibody reagents and viability dyes. The following antibodies were 
used for flow cytometry: FITC anti–T-bet (clone 4B10), Pacific Blue anti-
CD45RA (HI100), APC-H7 anti–interferon- (4S.B3), and Pacific Blue 
anti-CD57 (HCD57; BioLegend); APC anti-Eomes(WD1928) and eFluor780 
anti-CD127 (eBioRDR5; eBioscience); APC-H7 anti-CD27 (M-T271), 
APC anti–PD-1 (MIH4), Alexa Fluor 647 anti-STAT4 (pY693; 38/pStat4), 
PerCP anti-CD3 (SK7), V500 anti-CD8 (SK1), V450 anti-CD8 (RPA-T8), 
PerCP anti-CD14 (MP9), and PerCP anti-CD19 (SJ25C1; BD). 7-AAD 
(BD) was used as viability dye in ex vivo stainings, whereas FVD eFluor450 
(eBioscience) was used for fixed cells.
Synthetic peptides, pentamers, and cytokines. The following MHC-I 
pentamers were used for the detection of epitope-specific CD8 T cells: HBV 
core antigen 18–27 FLPSDFFPSV, HBV polymerase 573–581 FLLSLGIHL, 
HBV envelope 183–191 FLLTRILTI, HCV-NS3 1406–1415 KLVALGINAV, 
EBV BMLF-1 259–267 GLCTLVAML, and Flu MP 58–66 GILGFVFTL (all 
with MHC-I A0201 background); HCV-NS3 1436–1444 ATDALMTGF 
(HLA-A0101); HCV-NS5 2588–2596 RVCEKMALY (HLA-A0301); HCV 
core 41–49 GPRLGVRAT (HLA-B0701) and HCV-NS3 1359–1367 HPNIE-
EVAL (HLA-B3501). All MHC-I pentamers were PE-labeled and obtained 
from ProImmune. All corresponding peptides were synthesized by EMC micro-
collections and used for the in vitro stimulation of specific CD8 T cells. For 
stimulation experiments, recombinant human IL-2 (R&D Systems) and IL-12 
p70 (eBioscience) were used. The following cytokines were screened for induc-
tion of T-bet in CD8 T cells: IL-18 (10 ng/ml), IL-21 (25 ng/ml), IL-23 (50 ng/ml), 
interferon- (2,000 IU/ml), interferon- (2,000 IU/ml; eBioscience).
PBMC stimulation. PBMCs were cultured for 3 d in RPMI 1640 medium 
(Invitrogen) containing 2 mM l-glutamine, 1 mM sodium pyruvate, 
100 U/ml of penicillin, 100 µg of streptomycin/ml and 5% human AB 
serum. In the cytokine-stimulated groups, IL-2 (20 IU/ml) and/or IL-12 
(50 pg/ml) were added on day 0. Antigen-stimulated groups received 5 µg/ml 
antigen on day 0 and were restimulated with the same dose of antigen on day 3. 
On day 3, cells were incubated for 6 h under stimulating conditions in the 
presence of Brefeldin A (eBioscience). After stimulation, cells were prepared 
for flow cytometry by intracellular cytokine staining.
PBSE proliferation assay. 500,000 PBMCs per condition were stained in 
120 µM PBSE (Life Technologies). Cells were distributed on a 96-well 
round-bottomed cell culture plate in 100 µl of culture medium and were 
cultured in the presence or absence of antigen (5 µg/ml) for 7 d. On day 4, 
IL-2 (20 IU/ml) and/or IL-12 (50pg/ml) were added. On day 7, cells were 
collected and stained for flow cytometry.
Flow cytometry. 2–3 × 106 PBMCs were stained with MHC-I pentamers 
according to the manufacturer’s instructions. After staining with viability dyes 
and antibodies specific for surface markers, cells were fixed with intracellular 
fixation buffer and permeabilized with permeabilization buffer (both from 
eBioscience). After the permeabilization step, cells were stained with intracel-
lular markers (T-bet, Eomes, and interferon-). For ex vivo staining, pentamer+ 
Table 2. Patient characteristics
Group n Female /male Age (mean) GPT(U/l; mean) Viral load (mean) HCV GT1 Anti-HBe ± n.d.
arHBV 19 6/13 38.4 2,567 19.6 × 106 cop/ml - 8 6 5
cHBV 24 7/17 44.6 59.5 18.3 × 103 cop/ml - 13 5 6
aHCV 14 6/8 53.5 984 6.9 × 106 IU/ml 9 -
cHCV 7 3/4 44.8 81.9 0.8 × 106 IU/ml n.d. -
rHBV 5 0/5 47.4 normal negative - -
rHCV 7 3/4 53.3 normal negative n.d. -
aEBV 3 2/1 44.3 n.d. negative - -
healthy 9 8/1 39.1 normal negative - -
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